Ipsen (FR:IPN) has released an update.
Iqirvo (elafibranor), a new treatment for primary biliary cholangitis (PBC) by Ipsen, has been approved by the European Commission, marking the first advancement in nearly a decade for this rare liver disease. The approval is based on the ELATIVE phase III trial results, which showed a significant improvement over placebo in managing disease progression and symptoms like itch. This medication is a first-in-class oral PPAR agonist, providing a new option for patients who do not respond to or cannot tolerate the current first-line therapy, UDCA.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
